Trials
Search / Trial NCT05645133

QPlus Pediatric Reference Interval

Launched by HEMOSONICS LLC · Dec 1, 2022

Trial Information

Current as of January 14, 2025

Terminated

Keywords

Q Plus Quantra Pediatric Reference Range

ClinConnect Summary

Single center observational study of the pediatric patient population (\< 18yrs) with normal coagulation function to determine the reference range interval for the clotting parameters reported by the Quantra QPlus system.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • \<18yrs
  • Scheduled for procedure requiring anesthesia
  • Access to blood sampling
  • Consented
  • Exclusion Criteria:
  • \>18yrs of age
  • pre-term babies
  • patients with know hematological disorders
  • Difficult to obtain blood sampling
  • Has received a blood product transfusion within the last 24hrs.
  • Legal guardian unwilling to consent

Trial Officials

Christopher Tirotta, MD

Principal Investigator

Nicklaus Childrens

About Hemosonics Llc

Hemosonics LLC is a pioneering biotechnology company focused on advancing diagnostic solutions for the management of bleeding and clotting disorders. With a commitment to innovation, Hemosonics develops cutting-edge technologies that enable rapid and accurate assessment of hemostasis, empowering healthcare professionals to make informed clinical decisions. Through rigorous clinical trials and research initiatives, Hemosonics aims to enhance patient outcomes and improve the standard of care in critical care settings. The company is dedicated to fostering partnerships within the medical community to drive advancements in patient diagnostics and treatment strategies.

Locations

Miami, Florida, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials